Why ADCs Are a Bioanalytical Category of Their Own
Antibody-drug conjugates (ADCs) are one of the most complex therapeutic modalities in the modern oncology pipeline. An ADC consists of a monoclonal antibody linked to a cytotoxic small molecule payload via a chemical linker. The three components are designed to work in concert: the antibody targets a tumour-associated antigen, the linker controls where and when the payload is released, and the payload kills the targeted cell.
From a bioanalytical perspective, this architecture creates a challenge that neither traditional large molecule nor traditional small molecule methods can fully address on their own. A complete ADC bioanalytical programme must characterise the full molecule, the released payload, the total antibody, and the drug-to-antibody ratio as it changes in circulation. Each of these analytes requires a different measurement approach, and each tells a different story about the safety and efficacy of the drug.
The Four Key Analytes in an ADC Bioanalytical Programme
| Analyte | What It Represents | Primary Method | Key Regulatory Consideration |
| Total antibody | All antibody species, conjugated and unconjugated | Ligand-binding assay (LBA) using anti-idiotype or anti-Fc reagent | Reflects antibody clearance; required for full PK characterisation |
| Conjugated antibody (ADC) | Antibody species carrying at least one payload molecule | LBA using payload-specific or linker-specific detection arm | Correlates with pharmacological activity |
| Drug-to-antibody ratio (DAR) | Average number of payload molecules per antibody in circulation | Hydrophobic interaction chromatography (HIC) or LC-MS | DAR changes with linker stability; important for safety and PK interpretation |
| Free payload (small molecule) | Unconjugated cytotoxic warhead released in circulation | LC-MS/MS with matrix-appropriate extraction | Critical for safety assessment; subject to small molecule method validation requirements |
Ligand-Binding Assays for ADC Characterisation
Ligand-binding assays, including enzyme-linked immunosorbent assays (ELISA) and electrochemiluminescence (ECL) platforms such as Meso Scale Discovery (MSD), are the standard approach for measuring total antibody and conjugated antibody concentrations. The critical reagent challenge for ADC LBAs is the availability of a well-characterised anti-idiotype antibody or an alternative capture or detection reagent that is specific enough to distinguish the analyte of interest from other antibody species in the sample.
Assay development and validation for LBAs used in ADC programmes must follow the ICH M10 guideline on bioanalytical method validation, which specifies the validation parameters and acceptance criteria for regulated bioanalysis. For ADC LBAs, particular attention must be paid to selectivity (demonstrating the assay is not confounded by the unconjugated antibody or by anti-drug antibodies) and to the stability of the analyte in the biological matrix.
LC-MS/MS for Free Payload Quantification
The cytotoxic small molecule payload released from an ADC, whether through linker cleavage in the tumour environment or off-target release in circulation, must be quantified in plasma and, in some studies, in tissue samples. LC-MS/MS is the method of choice for small molecule payload quantification, offering the sensitivity and specificity needed to measure cytotoxic payloads at the very low concentrations typically encountered in non-clinical and clinical studies.
Matrix effects are a particular concern for payload assays in plasma, given the potential for the plasma proteins and lipids to suppress ionisation. Sample preparation strategies including protein precipitation, liquid-liquid extraction, and solid-phase extraction must be evaluated and selected to minimise matrix effects while maintaining adequate sensitivity.
Critical Considerations for ADC Assay Validation
Analyte Stability
ADC molecules are susceptible to degradation by multiple mechanisms: linker hydrolysis, deconjugation of the payload, antibody aggregation, and payload-driven instability. Understanding how each analyte behaves from the time of blood collection through sample processing and storage to analysis is essential for producing reliable data. Stability evaluations should cover bench-top stability, freeze-thaw cycles, and long-term frozen storage at the intended storage temperature.
Reference Standard Characterisation
The reference standard used to calibrate an ADC assay is itself a complex molecule with a distribution of DAR species. The characterisation of the reference standard, including its average DAR, the DAR distribution, and the antibody concentration, directly affects the accuracy of the assay. Reference standard characterisation using HIC, SEC, and LC-MS is a standard part of an ADC bioanalytical method development programme.
Anti-Drug Antibody (ADA) Interference
ADAs can interfere with ADC PK assays by binding to the drug molecule and either blocking the assay reagents or enhancing clearance. Understanding the extent of ADA interference, and whether a cut-point approach is needed to flag samples with potentially confounded PK data, is an important element of the assay validation strategy for ADC programmes.
Ardena’s ADC Bioanalytical Capabilities at Assen
Ardena’s bioanalytical facility in Assen, the Netherlands, provides dedicated ADC bioanalysis services including LBA development and validation for total antibody and conjugated antibody, LC-MS/MS for free payload quantification, and immunogenicity assessment for ADA detection. The facility operates under GLP and GCP conditions for regulated bioanalysis and is equipped with MSD and ELISA platforms for LBAs and high-sensitivity triple-quadrupole mass spectrometers for small molecule work.
Ardena’s bioanalytical scientists have experience supporting ADC programmes from early non-clinical characterisation through Phase I and Phase II clinical studies, and can advise on assay strategy, critical reagent sourcing, and the ICH M10 validation requirements that apply to regulated ADC bioanalysis.
